Has Noel Santo Domingo received payments from drug or device companies?

Yes. Drug and device makers reported $4,325 in general payments to Noel Santo Domingo across 184 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Noel Santo Domingo did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Noel Santo Domingo come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Noel Santo Domingo

Cardiovascular Disease · Petaluma, CANPI 1992797435

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $3,883 of the $4,325 with a category attached, or 89.8%. It is spread thinly across 23 manufacturers, the largest accounting for just 20.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,889 and has fallen 98.4% since, to $29 in 2023.

$4,325in general payments, 2019–2025

Across 184 payments — averaging $23.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Medtronic$902
Amgen$419
Novartis$391
Edwards Lifesciences$303
Kowa Pharmaceuticals America, Inc.$256
Abbott$246
plus $2K from 17 others

What the payments were for

Travel & lodging$42910%
Food & beverage$3,88390%
Education$130%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Medtronic(2 entities)	15	$902
Amgen	32	$419
Novartis	21	$391
Edwards Lifesciences	7	$303
Kowa Pharmaceuticals America, Inc.	10	$256
Abbott	5	$246
Johnson & Johnson	13	$195
Bardy Diagnostics, Inc.	4	$193
Amarin Pharma, Inc.	14	$191
Esperion Therapeutics, Inc.	8	$189
Boehringer Ingelheim	9	$188
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)	12	$149
AstraZeneca	8	$135
Preventice Services, LLC	2	$101
Pfizer	4	$90
Sanofi-aventis U.S. LLC	4	$81
Boston Scientific	4	$73
Regeneron Healthcare Solutions, Inc.	3	$57
Merck	2	$45
Actelion Pharmaceuticals US, Inc.	2	$45
E.r. Squibb & Sons, L.L.C.	2	$38
Irhythm Technologies, Inc.	2	$27
AbbVie	1	$11

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,325 in reported general payments places this provider in the 60th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California →

Other cardiovascular disease in Petaluma

Ted LoveHillsborough$102.8M
Paul KurthSanta Barbara$6.1M
Jason RogersSacramento$4.4M
Matthew BudoffTorrance$3.6M
Eric Topolla Jolla$2.2M
Cathleen Bairey-MerzLos Angeles$1.2M
Gagan SinghSacramento$1.2M
Pam Taubla Jolla$1.2M
Wilber SuStanford$1.1M
Thomas SmithSacramento$942K

See the full list for California →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →